The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin

References

• Forssen E.A., Tokes Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun. 1979; 91: 1295–1301
   PubMed Web of Science ®Google Scholar
• Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P.S. Liposomal protection of Adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980; 40: 1532–1537
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 1982; 42: 4734–4739
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Tai L.C.L., Ko D.S.C., Masin D., Ginsberg R.S., Cullis P.R., Bally M.B. Influence of vesicle size, lipid composition and drug to lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49: 5922–5930
   PubMed Web of Science ®Google Scholar
• Allen T.M. Stealth liposomes: avoiding reticuloendothelial uptake. “Liposomes in the Therapy of Infectious Deseases and Cancer.”, G. Lopezberestein, I.J. Fidler. Alan R. Liss, Inc, New York 1989; 405–415
   Google Scholar
• Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 1989; 81: 1484–1488
   PubMed Web of Science ®Google Scholar
• Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992; 52: 891–896
   PubMed Web of Science ®Google Scholar
• Ahmad I., Longenecker M., Samuel J., Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 1993; 53: 1484–1488
   PubMed Web of Science ®Google Scholar
• Hwang K.J. Liposome pharmacokinetics. “Liposomes: from Biophysics to Therapeutics.”, M.J. Ostro. Marcel Dekker, New York 1987; 109–156
   Google Scholar
• Mayer L.D., Tai L.C.L., Bally M.B., Mitilenes G.N., Ginsberg R.S., Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta 1990; 1025: 143–151
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a raped extrusion procedure. Biochim. Biophys. Acta 1986; 858: 161–168
   PubMed Web of Science ®Google Scholar
• Nayar R., Hope M.J., Cullis P.R. Generation of large unilamellar vesicles from long chain saturated phosphatidylcholines by extrusion technique. Biochim. Biophys. Acta 1989; 986: 200–205
   Web of Science ®Google Scholar
• Scherphof G.L., Kuipers F., Denksen J.T.P., Spanyer H.H., Wonk R.J. Liposomes in vivo: conversion of liposomal cholesterol to bile salts. Biochem. Soc. Trans. 1987; 15: 625–628
   Google Scholar
• Olson F., Mayhew E., Maslow D., Rustum Y., Szoka F. Caracterization, toxicity and therapeutic efficacy of Adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. 1982; 18: 167–176
   PubMedGoogle Scholar
• Harrigan P.R., Wong K.F., Redelmeier T.E., Wheeler J.J., Cullis P.R. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim. Biophys. Acta 1993; 1149: 329–338
   Google Scholar
• Kirby C., Clark J., Gregoriadis G. Cholesterol content of small unilamellar lipsoomes controls phospholipid loss to high density lipoproteins. FEBS Lett. 1980; 111: 324–328
   PubMed Web of Science ®Google Scholar
• Gabizon A., Price D.C., Huberty J., Bresalier R.S., Paphadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990; 50: 6371–6378
   PubMed Web of Science ®Google Scholar
• Huang S.K., Mayhew E., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 Colon Carcinoma. Cancer Res. 1992; 52: 6774–6781
   PubMed Web of Science ®Google Scholar
• Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992; 52: 5135–5143
   PubMed Web of Science ®Google Scholar
• Druckmann S., Gabizon A., Barenholz Y. Separation of liposome-associated doxorubicin from protein-bound and free doxorubicin: implications for pharmacokinetic studies. Biochim. Biophys. Acta 1989; 980: 381–384
   PubMed Web of Science ®Google Scholar
• Thies R.L., Cowens D.W., Cullis P.R., Bally M.B., Mayer L.D. Method for rapid separation of liposome-associate doxorubicin from free doxorubicin in plasma. Analytical Biochem. 1990; 188: 65–71
   PubMed Web of Science ®Google Scholar
• Bally M.B., Nayar R., Masin D., Hope M.J., Cullis P.R., Mayer L.D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta 1990; 1023: 133–139
   PubMed Web of Science ®Google Scholar
• Cowens J.W., Creaven P.J., Greco W.R., Brenner D.E., Tung Y., Ostro M., Pilkiewicz F., Ginsberg R., Petrelli N. Initial (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993; 53: 2796–2802
   PubMed Web of Science ®Google Scholar
• Batist G., Panasci L., Gruner P., Leyland-Jones B., Pilkiewicz F., Haccoun L. Phase II study of liposomal doxorubicin (TLC D-99) in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1992; 11: 82
   Google Scholar
• Northfield D.W., Russel J., Anderson M., Lang J., Volberding P.A. Pharmacokinetics, tumor localization and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposis sarcoma (AIDS-KS). Proc. Am. Soc. Clin. Oncol. 1993; 12: 51
   Google Scholar